MANAGEMENT OF DELIRIUM IN AN ACUTE CARE HOSPITAL

Authors: Katharina Iltingreuke1, Anna Roos1, Patricia Ohrmann2, Thomas Duning3*, Georg Hempel3*

1 Department of Neurology, University Hospital of Muenster, 48149 Muenster, Germany
2 Department of Psychiatry, University Hospital of Muenster, 48149 Muenster, Germany
3 Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, Westfälische Wilhelms-University of Muenster, 48149 Muenster, Germany

* These authors contributed equally

Background
Delirium is a common and severe condition among hospitalized older people. Due to the dominating symptoms, like drowsiness and inactivity, the hypactive delirium receives less clinical attention than the hyperactive delirium characterized by agitation and restlessness. Because of this, 30 to 60% of delirium are undiagnosed (1). The consequences, especially for the elderly people, are dramatic: It leads to a longer lasting cognitive decline and impairments in every aspect of quality of life. Because of these clinical aspects, the mortality is temporary 20-fold increased (2). The most important predisposing risk factors for a delirium are the age, the cognition, the multimorbidity and the associated polypharmacy. Many drugs have a strong anticholinergic risk profile, which leads to an acute neurotransmitter-dysbalance. 30 % of delirium are induced by drugs (3). Advances in prevention, diagnosis and treatment can improve recognition and risk stratification of delirium and its consequences. For this purpose the University Hospital of Muenster established a multidisciplinary department, which developed nonpharmacological and pharmacological guidelines for prevention, diagnosis and treatment of delirium. It consist of neurologists, pharmacists and specialized nursing staff. We conducted an open label randomized controlled trial to show the effectiveness of these multidisciplinary approaches in surgical and nonsurgical patients aged 65 years and over to reduce the risk of delirium.

Methods
- **Patient population:**
  - Aged 65 years and over
  - Three days or longer hospitalization in trauma surgery, orthopedics or nephrology
  - At admission every patient ≥ 65 years is screened by the Montreal Cognitive Assessment (MoCA) to objectively the risk for getting a delirium
  - Enrollment by MoCA > 26 points
  - From January 2016 to October 2017, 1694 patients ≥65 years were screened at admission by using the MoCA. Overall, 1089 patients (64%) had an elevated risk of getting a delirium (MoCA>26 points) (Fig.1). A total of 723 patients (43%) could be included and randomized
  - The intervention group (n=370) received our innovative standardized management of delirium:
    - Specialized nursing
    - Constant detection of delirium by using the Confusion Assessment Method (CAM) on the first three days or on the first three postoperative days
    - Pharmacological management:
      - Medication optimization at admission: (avoiding inappropriate drugs with a high risk of anticholinergic effects on the central nervous system )

- **Substances for delirium treatment:**
  - Control group
  - Intervention group

<table>
<thead>
<tr>
<th>Substances for delirium treatment</th>
<th>Control group</th>
<th>Intervention group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haloperidol</td>
<td>6%</td>
<td>0%</td>
</tr>
<tr>
<td>Midolprim</td>
<td>3%</td>
<td>0%</td>
</tr>
<tr>
<td>Low potency antipsychotics</td>
<td>5%</td>
<td>0%</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>5%</td>
<td>4%</td>
</tr>
</tbody>
</table>

- **Results:**
  - Treatment of delirium by using the innovative medication standard (Fig.2), which has been developed by an interdisciplinary team. It is adapted to geriatric patients and the management of an acute care hospital
    - The control group (n=553) was treated as usual without any standardized strategies
    - The cognitive outcome of each patient was assessed by a second MoCA before discharge
    - Follow up: Every patient, who develops a delirium, will be screened by a third MoCA to evaluate and compare the cognitive longterm course
    - Second follow up: Every patient in each group will get an interview to note the mortality, the care degree and the score of the Instrumental – Activity of Daily Living Scale (I-ADL)

  The duration of delirium in the intervention group was reduced by half, compared to the control group (4 vs. 8 days (p<0.001)) (Fig.3).

  The risk of a manifest delirium was more than 50% higher in the control group (OR 0.35, 95%CI 0.21–0.59) compared to the intervention group. (15% control group vs. 6% intervention group)

  In a case-control study, we designed for evaluation of medication for delirium treatment, we could initially show that the inappropriate PRN medication of high-potency antipsychotics could be reduced by 100% in the intervention group. Furthermore the use of benzodiazepines could be reduced by 90 % due to optimized medication strategies by clinical pharmacists (Tab.1).

  Furthermore the results emphasize the importance of clinical pharmacists: The inappropriate use of non-evidence-based medication of delirium (e.g. inappropriate application of antipsychotics, benzodiazepines and anticholinergic substances) could be reduced by intensive training of medical staff and pharmaceutical counseling.

Conclusion
The current results of our study have proven that not every delirium can be prevented, but the rate and the duration of delirium can be significantly reduced.

Considering the demographic change, we recommend to implement a multidisciplinary approach for consistent and standardized management of delirium.

References